Ben Wiegand, Ph.D.
The modern emergence of digital signals associated with personal health combined with the technical advances to extract meaningful insights from these data streams will unlock the ability to deliver the right healthcare to the right person at the right time.
Ben Wiegand serves as senior vice president leading the Research & Clinical group at Optum Labs, the research and development arm of UnitedHealth Group, where he directs efforts to improve healthcare delivery for patients, payers, and providers.
Wiegand’s teams leverage data and scientific insights to uncover critical healthcare needs and create personalized, effective, engaging, and equitable solutions. They focus on disruptive innovation and combine digital, wearable, pharmaceutical, and nutritional interventions coupled with early detection and diagnosis to help people live healthier lives.
Throughout his 25+ year career in healthcare, Wiegand has honed his innovation expertise and marshalled a powerful network of collaborators to effect meaningful change. His long-term goal is the ultimate paradigm shift in healthcare—the move from disease management to disease interception and prevention.
Earlier at Johnson & Johnson and Janssen, Wiegand piloted new business and funding models, accelerated growth, and scouted emerging scientific areas to deliver innovative solutions. His passions extend to the inflammasome, the microbiome, digital therapeutics, and big data.
Prior to Johnson & Johnson, Wiegand worked at Procter & Gamble on cleansing and beauty solutions. He received a BS in Chemistry from the University of Illinois and an M.A. and Ph.D. in Physical Chemistry from Harvard University.
Wiegand’s teams leverage data and scientific insights to uncover critical healthcare needs and create personalized, effective, engaging, and equitable solutions. They focus on disruptive innovation and combine digital, wearable, pharmaceutical, and nutritional interventions coupled with early detection and diagnosis to help people live healthier lives.
Throughout his 25+ year career in healthcare, Wiegand has honed his innovation expertise and marshalled a powerful network of collaborators to effect meaningful change. His long-term goal is the ultimate paradigm shift in healthcare—the move from disease management to disease interception and prevention.
Earlier at Johnson & Johnson and Janssen, Wiegand piloted new business and funding models, accelerated growth, and scouted emerging scientific areas to deliver innovative solutions. His passions extend to the inflammasome, the microbiome, digital therapeutics, and big data.
Prior to Johnson & Johnson, Wiegand worked at Procter & Gamble on cleansing and beauty solutions. He received a BS in Chemistry from the University of Illinois and an M.A. and Ph.D. in Physical Chemistry from Harvard University.
